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In our previous study, we showed that fatty acids from CLA-enriched egg yolks (EFA-CLA) reduced the proliferation of breast
cancer cells; however, the molecular mechanisms of their action remain unknown. In the current study, we used MCF-7 breast
cancer cell line to determine the effect of EFA-CLA, as potential ligands for peroxisome proliferator-activated receptors (PPARs),
on identified in silico PPAR-responsive genes: BCAR3, TCF20, WT1, ZNF621, and THRB (transcript TR𝛽2). Our results showed
that EFA-CLA act as PPAR ligands with agonistic activity for all PPAR isoforms, with the highest specificity towards PPAR𝛾. In
conclusion, we propose that EFA-CLA-mediated regulation of PPAR-responsive genes is most likely facilitated by cis9,trans11CLA
isomer incorporated in egg yolk. Notably, EFA-CLA activated PPARmore efficiently than nonenriched FA as well as synthetic CLA
isomers. We also propose that this regulation, at least in part, can be responsible for the observed reduction in the proliferation of
MCF-7 cells treated with EFA-CLA.
1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors. Various fatty acids
and their metabolic derivatives act as natural ligands for
PPARs [1]. Some, including linoleic, linolenic, and arachi-
donic acid, were found to activate PPARs even at micro-
molar, physiologically relevant concentrations [2]. Hydrox-
yoctadecadienoic acids (HODEs), products of linoleic acid
oxidation as well as arachidonic acid metabolite 15d-PGJ2
(15-deoxyprostaglandin J2), were also associated with PPAR
activation [3, 4].
It has been suggested that ligand-dependent activation of
PPARs results in the inhibition of proliferation in somemodel
cancer cell lines [5–7]. In particular, PPAR𝛾 isoform was
shown to reduce cancer cell proliferation as well as regulate
cell differentiation, activate apoptosis, and inhibit angiogen-
esis [8–10]. Specifically, the administration of specific PPAR𝛾
agonist resulted in cells arrest in G1 phase and inhibited
proliferation [5, 11]. However, available literature presents
also contradicting results. In some studies, PPAR𝛾 specific
antagonist, T0070907, significantly reduced proliferation and
migration of breast cancer cells [12, 13].
Conjugated linoleic acid (CLA) term includes several
isomers of linoleic acid, with two main isomers: cis9,trans11
(80–90% of total CLA) and trans10,cis12. Available literature
shows that CLA acts as a potent PPARs ligand and is involved
in modulating lipid metabolism through PPAR-mediated
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pathways [14]. However, data showed isomer-specific activity
of CLA; specifically, cis9,trans11 was characterized as PPAR
agonist [15, 16] while trans10,cis12 was shown to inhibit the
activity of synthetic PPAR agonists [15]. In addition, studies
showed potential antitumor properties of cis9,trans11 [17–20]
while the opposite effectwas observed for trans10,cis12 isomer
[18].
PPARs act as transcription factors and regulate the
expression of dependent genes by binding to their PPREs. A
significant number of genes regulated by PPARs have been
described; however, the list is not exhaustive and is constantly
being updated as new results are being published from both
experimental data and bioinformatics analyses of promoter
regions and PPRE consensus sequences. In the current study,
we applied those tools to identify in silico PPRE selected
genes involved in cell cycle progression and proliferation.
Next, we analyzed the effect of synthetic cis9,trans11CLA and
trans10,cis12CLA isomers as well as a mixture of fatty acids
extracted from CLA-enriched and nonenriched egg yolk on
the expression of those genes. To the best of our knowledge,
our study is the first to address the effect of CLA incorporated
in fatty acids profile of the egg yolk; we expect that activity of
CLA in such a “bioorganic” form may deviate from that of
a synthetic form. The presence of other fatty acids in an egg
yolk, which themselves can act as potential ligands for PPARs,
may modulate the action of CLA; therefore, our data may
be particularly important for the evaluation of CLA-enriched
food products.
2. Materials and Methods
2.1. Production of CLA-Enriched EggYolks. Production ofCLA-
enriched egg yolks was performed in the National Research
Institute of Animal Production in Krakow (Poland), as per
the recommendations of the Local Animal Ethics Committee
(approval number: 851/2011) as described previously [21].
Eggs were collected and stored at 4∘C, and yolks were
separated from albumen, homogenized, and frozen at −20∘C.
Sampleswere then lyophilized and again stored at−20∘Cuntil
further analyses.
2.2. Extraction and Analysis of Fatty Acids Composition.
Lipids from control and CLA-enriched yolks were extracted
by using modified Folch method [22] as described previously
[23]. 10mg of each lipid extract was subjected to saponifi-
cation with 0.5M KOH/methanol followed by methylation
with 14% (v/v) BF3/methanol and extraction with hexane.
Fatty acid methyl esters (FAME) were analyzed by GC/MS as
described previously [23].
2.3. CLA Isomers and Agonists/Antagonists of PPAR.
cis9,trans11CLA and trans10,cis12CLA isomers (Nu-Chek
Prep, USA) were dissolved in ethanol and stored under
nitrogen in −20∘C and were introduced to cell cultures at
final concentrations corresponding to their concentration
in CLA-enriched egg yolk: cis9,trans11 at 30 𝜇M and
trans10,cis12 at 12 𝜇M.
The synthetic agonists and antagonists for PPAR𝛼
(WY14643 andGW-6471), PPAR𝛿 (GW-0742 andGSK0660),
and PPAR𝛾 (pioglitazone (PIO), troglitazone, and T0070907)
were prepared as per appropriate protocols of the manufac-
turer. Respective concentrations were selected based on their
EC/IC50 characteristics and confirmed for MCF-7 cell line
using Cytotoxicity LDH Test (Roche, Poland).
2.4. Cell Cultures. The human breast adenocarcinoma cell
line MCF-7 (ATCC HTB22TM) was purchased from the
American Type Culture Collections. Cells were cultured in
appropriate medium (Sigma-Aldrich, MO, USA) as per the
ATCCprotocol with the addition of 10% FBS (Sigma-Aldrich,
MO, USA).
Cell viability was determined by Crystal Violet Assay
(Sigma-Aldrich, MO, USA).
2.5. Fatty Acid Treatment. The experimental medium con-
tained MEM supplemented with 10% FBS and appropri-
ate treatment: (a) fatty acids extract at 0.5mg/mL from
CLA-enriched egg yolks (EFA-CLA), (b) fatty acids extract
at 0.5mg/mL from nonenriched egg yolks (EFA), (c)
cis9,trans11 synthetic isomer (final concentration at 35𝜇M),
(d) trans10,cis12 synthetic isomer (final concentration at
13 𝜇M), (e) untreated cell control (empty control, EC), and
(f) negative control (NC; ethanol at final concentration
0.1%). Synthetic PPARs agonists and antagonist were used
as positive controls for PPAR𝛼 (10 𝜇M WY14643 and 10 𝜇M
GW-6471), PPAR𝛿 (2𝜇M GW-0742 and 1𝜇M GSK0660),
and PPAR𝛾 (40 𝜇M PIO, 10 𝜇M troglitazone, and 10 𝜇M
T0070907). Each treatment included 3 biological and 3
technical replicates.
2.6. Plasmids. PPAR expression vectors were prepared using
Gateway Cloning System (Thermo Fisher, USA). Briefly,
PPARA (CR456547_1), PPARD (NM_006238.4), and PPARG
(NM_015869.4) ORF sequences were synthesized, opti-
mized for the expression in human cells, and cloned into
the pDONR221 Entry Vectors (GeneArt, Thermo Fisher,
USA). Subsequently, the ORF inserts were transferred into
pcDNA6.2/N-EmGFP-DEST Destination Vectors (Thermo
Fisher, USA) under the CMV promoter control via Clonase
II Recombination Reaction.
2.7. Cell Transfection with PPAR Encoding Plasmids. Cell
lines with PPARA, PPARD, and PPARG overexpression
were obtained via transient transfections with pcDNA6.2/N-
EmGFP-DEST vectors containing respective human PPAR
ORF. MCF-7 cells were seeded on 12-well plates, at 1 ×
105 cells per well. 24 h after seeding, cells were transiently
transfected with 1.5 𝜇g of PPAR encoding plasmids using
Lipofectamine (Thermo Fisher Scientific, MA, USA) in
OPTI-MEM medium (Thermo Fisher Scientific, MA, USA).
24 h after transfection, the growthmediumwas replaced with
selective MEM medium with 10% FBS and 5.0 𝜇g/mL blas-
ticidin (BioShop, Canada). Transfected cells were cultured
until confluency.
Real-time PCR and western blot method were performed
to confirm the presence of PPAR plasmids after transfection
(Figure S1 and Table S2, Supplementary Material available
online at https://doi.org/10.1155/2017/2865283).
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2.8. Transfection with PPRE Plasmid. Cell lines overexpress-
ing, respectively, PPARA, PPARD, and PPARG were seeded
on the 12-well plates, at 1 × 105 cells per well. After 24
hours, cells were transfected with 0.7𝜇g X3 PPRE-TK-
luc plasmid (Cat. # 1015, Addgene, USA) and 0.7 𝜇g pRL
control (Cat. # E2261, Promega, WI, USA) using Lipofec-
tamine (Thermo Fisher Scientific, MA, USA) in OPTI-MEM
medium (Thermo Fisher Scientific, MA, USA).
2.9. Dual-Luciferase Assay. 24 hours after transfection with
PPRE plasmid, the medium was again replaced with MEM
medium containing 10% FBS and appropriate experimental
treatment as described above. 24 hours after treatment, cells
were harvested for isolation of protein luciferase.
The luciferase protein (Photinus pyralis and Renilla reni-
formis) detection was performed using Dual-Luciferase
Reporter Assay System (Promega, WI, USA) in GloMax
20/20 Single Tube Luminometer (Promega, WI, USA),
according to the manufacturer’s instructions.
2.10. In Silico Selection and Experimental Confirmation of
PPAR-Dependent Genes (PPAR-Responsive mRNAs). PPAR-
responsive genes were selected in silico by searching
for peroxisome proliferator hormone response elements
(PPREs, AGGTCANAGGTCA) within promoters and/or 5󸀠-
cis-regulatory regions of the promoters of genes involved
in cell cycle progression and proliferation. This search was
performed with NCBI Gene and Blast tools.
Experimentally, 24 hours after transfection with respec-
tive PPAR plasmids, the medium was replaced with MEM
medium containing 10% FBS and appropriate experimental
treatment as described above. 48 hours after treatment, cells
were harvested for mRNA isolation and RT-qPCR.
2.11. RNA Isolation, cDNA Synthesis, and RT-qPCR Analysis.
Total RNA was isolated from the cells using RNA isolation
kit for cell cultures (A&A Biotechnology, Poland). Reverse
transcription was performed on 1 𝜇g of total RNA usingMax-
ima First-Strand cDNA Synthesis kit for RT-qPCR (Thermo
Scientific, MA, USA). Quantitative verification of genes was
performed using CFX96 Touch Real-Time PCR Detection
System instrument (Bio-Rad, CA, USA) and SYBR Green
PrecisionMelt Supermix kit (Bio-Rad, CA,USA). Conditions
of individual PCR reactions were optimized for given pair of
oligonucleotide primers (Table S1, Supplementary Material).
Basic conditions were as follows: 95∘C for 10min, 45 PCR
cycles at 95∘C, 15 s; 59∘C, 15 s; 72∘C, 15 s, followed by melting
curve analysis (65–97∘C with 0.11∘C ramp rate and 5 acqui-
sitions per 1∘C). Results were normalized using at least two
reference genes (GAPDH, HPRT1, ACTB, or HSP90AB1) and
were calculated using the 2−ΔΔCT method [24].
2.12. Protein Isolation and Western Blot Analysis. Cell lysis
was carried out using Cell Lysis Buffer (Cell Signaling Tech-
nology, MA, USA) as per the manufacturer’s protocol. Total
protein quantification was performed using Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific, MA, USA).
Each western blot followed a similar procedure. Pro-
tein extract was separated on a polyacrylamide gel and
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Figure 1: Effect of fatty acids on MCF-7 cells viability. Values are
expressed as means ± SD for𝑁 ≥ 9, standardized to control (NC) as
100%. Statistical significance was based on 𝑡-test; ∗𝑝 < 0.05 versus
control.
transferred to a nitrocellulose filter (Bio-Rad, CA, USA) by
wet electroblotting. Subsequently, the immobilized proteins
were incubated with appropriate primary antibody, specific
for PPAR𝛼 (SAB2101852), PPAR𝛾 (SAB2101853), and PPAR𝛿
(AV32880) as well as for selected in silicoWT1 (SAB2102716),
THRB (AV36994), and TCF20 (SAB2106444) from Sigma-
Aldrich, MO, USA, or 𝛽-actin (#8457) or 𝛽-tubulin (#2128)
from Cell Signaling Technology, MA, USA. Finally, appro-
priate secondary antibody conjugated with horseradish per-
oxidase (#7074, Cell Signaling Technology, MA, USA) was
applied. Detection was executed by chemiluminescence,
using ClarityWestern ECL Substrate (Bio-Rad, CA, USA).
To remove the antibodies from the membrane, we used
western blot stripping buffer (Thermo Scientific, MA, USA).
2.13. Statistical Analysis. All experiments were performed
at least three independent times and measured in tripli-
cate. Shapiro-Wilk’s test was applied to assess normality of
distribution. An independent samples 𝑡-test was applied to
compare unpaired means between two groups. 𝑝 < 0.05
was considered statistically significant. All analyses were
performed using Statistica ver.12 (StatSoft, Tulsa, OK, USA).
3. Results
3.1. Cell Viability. Treatment with both extracts, EFA and
EFA-CLA, decreased viability of MCF-7 breast cancer cell
line compared to the control; however, the effect of EFA-CLA
was more evident compared to EFA. 72 h after treatment,
cell viability in EFA-CLA-treated group decreased by 50%
while for EFA the decrease in viability reached 32% (Figure 1).
Treatment with synthetic trans10,cis12CLA reduced cell via-
bility in a linear manner with incubation time, reaching 43%
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Figure 2: Experimental mechanism for studying the activity of EFA-CLA as a ligand for PPAR. DBD:DNA-binding domain specific for PPRE
sequence in promoter regions of genes regulated by PPAR; LBD: ligand-binding domain (e.g., EFA-CLA).
at 72 h. The reductive effect of cis9,trans11CLA isomer was
less evident and statistically significant only after 72 h (overall
reduction in viability by 15%).
3.2. Effects of EFA-CLA on Transcriptional Activity of PPARs.
To analyze the activity and specificity of various CLAs as
potential PPAR ligands, we applied the PPAR-dependent
luciferase expression model (Figure 2). We used specific
agonists and antagonists for each isoform of PPARs as
positive controls. Our results confirmed the expected effects
of selected agonists and antagonists (Figures 3(a)–3(c)). The
effect of experimental FA extracts varied. Compared to the
negative control, EFA-CLA significantly increased the activity
of PPAR𝛼 (202% of NC; 𝑝 < 0.05; Figure 3(a)), PPAR𝛿
(187.10% of NC; 𝑝 < 0.01; Figure 3(b)), and PPAR𝛾 (353%
of NC; 𝑝 < 0.001; Figure 3(c)). Compared to EFA extract,
EFA-CLA also showed statistically significant activation of
all PPAR isoforms (Figures 3(a)–3(c)). Synthetic cis9,trans11
isomer also activated significantly all PPARs, PPAR𝛼 (211%
of NC; 𝑝 < 0.05; Figure 3(a)), PPAR𝛿 (221.88% of NC;
𝑝 < 0.01; Figure 3(b)), and PPAR𝛾 (237% of NC; 𝑝 < 0.01;
Figure 3(c)). trans10,cis12CLA isomer had little or no effect
on the activation of PPAR𝛼 and PPAR𝛿 (Figures 3(a) and
3(b)); however, it reduced the activity of PPAR𝛾 (85% of NC;
𝑝 < 0.05; Figure 3(c)).
3.3. Selective Effect of FA on Transcriptional Activity of
PPARs. The selective effects of the studied FA as potential
PPAR ligands are shown in Figures 4(a)–4(d). EFA-CLA
was determined to be the most specific for PPAR𝛾 (3.5-fold
increase in activity, 𝑝 < 0.001; Figure 4(a)). EFA extract acted
as an antagonist towards both PPAR𝛼 and PPAR𝛿, while it
exhibited only negligible agonist activity on PPAR𝛿 (1.44-
fold increase in activity, 𝑝 > 0.05, Figure 4(b)). cis9,trans11
isomer showed agonist properties towards all PPAR isoforms,
with the strongest effect on PPAR𝛾 (2.37-fold increase in
activity, 𝑝 < 0.005; Figure 4(c)). trans10,cis12 isomer showed
no significant effect on transactivation of both PPAR𝛼 and
PPAR𝛿 (𝑝 > 0.05, Figure 4(d)), while it showed an antagonist
activity towards PPAR𝛾 (𝑝 < 0.01, Figure 4(d)).
3.4. Prediction of Potential PPRE-Dependent Genes In Silico.
The prediction of potential PPRE-responsive genes was per-
formed in silico.NCBI databasewas searched for the presence
of specific PPRE (peroxisome proliferator response element)
consensus sequences (AGGTCAAAGGTCA, AGGTCA-
GAGGTCA, AGGTCACAGGTCA, or AGGTCATAGGTC-
A) in the 5󸀠 region of genes linked to oncogenesis and
cell cycle (Figure 5). Seven genes were identified: BCAR3,
LZTS, SLC5A1, TCF20,WT1, ZNF621, and THRB (transcript
TR𝛽2), potentially regulated by PPARs (Table 1). THRB
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Figure 3: Effect of EFA-CLA on the activity of (a) PPAR𝛼, (b) PPAR𝛿, and (c) PPAR𝛾 based onmeasured luciferase activity in dual-luciferase
assay. Values are expressed as means ± SEM for 𝑁 ≥ 12, standardized to control (NC) as 100%. Statistical significance was based on 𝑡-test;
∗𝑝 < 0.05 versus NC or ∧𝑝 < 0.05 versus EFA.
Table 1: Identification of in silico putative PPAR-responsive genes.
Gene symbol Transcript Position NCBI reference sequence
BCAR3 AGGTCAGAGGTCA 93663502–93663514 NC_000001.11
LZTS1 AGGTCAAAGGTCA 20248971–20248983 NC_000008.11
SLC5A1 AGGTCACAGGTCA 32033858–32033870 NC_000022.11
TCF20 AGGTCATAGGTCA 42271609–42271621 NC_000022.11
WT1 AGGTCAGAGGTCA 32470961–3247097332470822–32470834 NC_000011.10
ZNF621 AGGTCAGAGGTCA 41052623–41052635 NC_000003.12
THRB (TR𝛽2) AGGTCACAGGTCA 24169753–24169765 NC_000003.12
BCAR3: breast cancer antiestrogen resistance 3; LZTS1: leucine zipper putative tumor suppressor 1; SLC5A: solute carrier family 5 member 1; TCF20:
transcription factor 20;WT1: Wilms tumor 1; ZNF621: zinc finger protein 621; THRB: thyroid hormone receptor beta.
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Figure 4: Selective effect of FA on PPARs expressed as fold difference versus control (100%), based on data fromFigure 3. Values are expressed
as means ± SEM for the𝑁 ≥ 12.
gene was identified by the presence of the PPRE consensus
sequence in a region of the alternative promoter for TR𝛽2
isoform (intron between the 4th and 5th exon). Among
identified potential PPRE-dependent genes, fewwere selected
for further experimental analyses, including TCF20, WT1
ZNF621, and THRB.
3.5. Effects of EFA-CLA on the Expression of PPAR-Regulated
Genes. Expression of selected PPAR-responsive genes (con-
taining PPRE) has been tested in response to various exper-
imental fatty acids as potential ligands for PPARA, PPARD,
or PPARG. Our results showed both agonist and antagonist
effects of studied experimental FA.
EFA-CLA added to the PPAR𝛾-overexpressing cells ele-
vated the expression ofTCF-20 over 3.2-fold andZNF621 over
3.1-fold, while decreasing the expression of WT1 gene 1.2-
fold. However, the latest may be explained, at least in part,
from the fact thatWT1 gene is cotranscribed with interfering
long, noncoding antisense RNA (WT1-AS) from the same
bidirectional promoter. For cells overexpressing PPAR𝛿, EFA-
CLA treatment resulted in the elevated expression of TCF-20
over 3-fold, while for the PPAR𝛼-overexpressing cellsZNF621
gene was upregulated 1.8-fold.
The strongest enhancement of TCF-20 expression (over
13-fold) was observed in PPAR𝛾- and PPAR𝛿-overexpressing
cells after treatment with trans10,cis12CLA. Interestingly, the
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expression of THRB (TR𝛽2 variant) gene was also strongly
increased by the treatment with trans10,cis12CLA over
18.15-, 17.2-, and 7.9-fold in PPAR𝛿-, PPAR𝛾-, and PPAR𝛼-
overexpressing cells, respectively, but not observed for EFA-
CLA-treated cells. Those results show that the presence of
other fatty acids in EFA-CLA mixture contributes to the
overall effect of FA treatment.
It is clear that the expression of the selected genes (TCF-
20, WT1, ZNF621, and THRB), which were identified for the
first time in this work as putative PPAR-responsive genes, was
altered in the presence of the used agents (Table 2) and that
among them TCF-20 was affected the most by EFA-CLA.
4. Discussion
Chicken egg enriched with conjugated linoleic acid (CLA)
via feed modification meets the criteria of the functional
food product. Based on Roberfroid’s [25] classification, CLA-
enriched egg can be considered as a conventional food
product that is intended to be consumed as a part of a normal
diet but is modified to contain biologically active substances,
that is, CLA isomers. It has been shown to have a beneficial
effect on physiological functions of the human body, in a way
that goes beyond its nutritional value, specifically by lowering
the risk of developing atherosclerosis [26]. Our previous
studies showed additional beneficial properties of CLA-
enriched eggs in reducing proliferation of breast cancer and
melanoma cells [23, 27]. The current manuscript supports
those findings as our new results showed that fatty acids
extract from CLA-enriched egg yolks (EFA-CLA) reduced
the viability of MCF-7 breast cancer cell line (Figure 1).
However, the molecular mechanism is not fully understood.
Comparison of the effect on cancer cell proliferation between
extracts from CLA-enriched and nonenriched egg yolks
could lead to the conclusion that it is simply the result of
the presence of CLA isomers incorporated in the egg yolk
lipids. Available literature would support such a hypothesis
as numerous studies showed an inhibitory effect, especially
for cis9,trans11CLA isomer, on tumor cells [28–32]. Indeed,
our analysis of FA profile of CLA-enriched egg yolk showed
that cis9,trans11CLA was incorporated more efficiently (3 : 1
ratio) than trans10,cis12 isomer [21] and therefore could
predominate in EFA-CLA. Interestingly, comparison of the
effect of synthetic CLA isomers with CLA-EFA from egg
yolk showed the advantage of the latter in reducing cancer
cell viability (Figure 1). The analysis of fatty acids profiles
between enriched and nonenriched egg yolks revealed not
only CLA incorporation but also unexpected, significant
change in SFA/MUFA ratio, specifically an increase in total
SFA concentration at the expense of MUFA.Thus, a question
8 PPAR Research
Ta
bl
e
2:
m
RN
A
ex
pr
es
sio
n
of
PP
A
Rs
-r
es
po
ns
iv
eg
en
es
in
PP
A
R-
tr
an
sfe
ct
ed
M
CF
-7
ce
lls
(w
ith
ov
er
ex
pr
es
sio
n
of
PP
A
Rs
)a
fte
rt
re
at
m
en
tw
ith
ex
pe
rim
en
ta
lF
A
or
sp
ec
ifi
ca
go
ni
st/
an
ta
go
ni
st
of
PP
A
R
fo
r4
8h
.
G
en
es
ym
bo
l
FC
va
lu
es
±
SD
EF
A
ve
rs
us
N
C
EF
A-
CL
A
ve
rs
us
N
C
cis
9,
tra
ns
11C
LA
ve
rs
us
N
C
tra
ns
10
,ci
s12
CL
A
ve
rs
us
N
C
A
go
ni
st
ve
rs
us
N
C
A
nt
ag
on
ist
ve
rs
us
N
C
(A
)m
RN
A
ex
pr
es
sio
n
of
PP
A
R𝛼
-d
ep
en
de
nt
ge
ne
s
TC
F-
20
−
1.
00
∗
±
0.
02
1.
02
±
0.
03
1.
10
±
0.
24
1.
70
∗
±
0.
14
1.
24
±
0.
14
−
3.
09
∗
±
0.
23
W
T1
−
1.
32
±
0.
11
−
1.
49
∗
±
0.
11
−
1,8
6∗
±
0.
07
−
1.
31
±
0.
23
1.
34
±
0.
26
−
2.
11
±
0.
18
ZN
F6
21
1.
36
±
0.
16
1.
80
∗
±
0.
20
−
2.
51
∗
±
0.
04
1.
09
±
0.
19
−
1.
06
±
0.
18
−
1.
20
±
0.
24
TH
RB
(T
R𝛽
2)
2.
49
±
0.
08
1.
15
±
0.
12
1.
74
∗
±
0.
09
7.
98
∗
±
0.
34
2.
54
±
0.
22
−
1.
77
∗
±
0.
00
(B
)m
RN
A
ex
pr
es
sio
n
of
PP
A
R𝛿
-d
ep
en
de
nt
ge
ne
s
TC
F-
20
2.
03
∗
±
0.
04
3.
08
∗
±
0.
03
7.
05
∗
±
0.
11
13
.0
2∗
±
0.
08
−
1.
43
∗
±
0.
01
2.
36
±
0.
08
W
T1
1.
18
±
0.
26
−
1.
38
∗
±
0.
03
−
1.
52
∗
±
0.
05
1.
71
±
0.
29
1.
90
∗
±
0.
04
1.
81
∗
±
0.
01
ZN
F6
21
1.
37
∗
±
0.
03
−
1.
29
∗
±
0.
02
1.
09
±
0.
16
−
1.
26
±
0.
19
−
1.
76
±
0.
11
−
1.
23
∗
±
0.
03
TH
RB
(T
R𝛽
2)
1.
61
∗
±
0.
02
1.
33
∗
±
0.
01
6.
67
∗
±
0.
09
18
.1
5∗
±
0.
11
1.
90
∗
±
0.
04
1.
81
∗
±
0.
01
(C
)m
RN
A
ex
pr
es
sio
n
of
PP
A
R𝛾
-d
ep
en
de
nt
ge
ne
s
TC
F-
20
2.
09
∗
±
0.
03
3.
21
∗
±
0.
04
6.
66
∗
±
0.
16
13
.4
8∗
±
0.
09
1.
92
∗
±
0.
03
2.
00
∗
±
0.
01
W
T1
−
1.
02
±
0.
04
−
1.
24
±
0.
06
−
1.
32
∗
±
0.
03
−
1.
02
±
0.
08
1.
48
±
0.
07
−
1.
47
∗
±
0.
03
ZN
F6
21
2.
99
∗
±
0.
01
3.
12
∗
±
0.
17
−
1.
13
±
0.
05
1.
46
±
0.
07
5.
97
∗
±
0.
20
3.
76
∗
±
0.
10
TH
RB
(T
R𝛽
2)
1.
09
±
0.
01
1.
14
±
0.
01
9.
96
∗
±
0.
10
17
.2
2∗
±
0.
13
−
1.
91
∗
±
0.
01
−
1.
58
∗
±
0.
00
FC
:f
ol
d
ch
an
ge
;N
C:
ne
ga
tiv
ec
on
tro
l.
A
go
ni
st/
an
ta
go
ni
st:
fo
rP
PA
R𝛼
,W
Y1
46
43
/G
W
-6
47
1;
fo
rP
PA
R𝛿
,G
W
-0
74
2/
G
SK
06
60
;f
or
PP
A
R𝛾
,t
ro
gl
ita
zo
ne
/T
00
70
90
7.
∗
𝑝
<
0
.0
5
.
PPAR Research 9
arises of whether it is an individual or combined effect of
CLA andmodified SFA/MUFA ratio in enriched egg yolks on
MCF-7 cell line [23].Weobserved that results ofCLA-EFAare
most likely achieved by the effect of both: incorporated CLA
isomers and other fatty acids in eggs modified organically
through hens’ diet [23]; however, this issue requires further
research.
It has been shown that PPAR agonists have different prop-
erties for individual PPAR isoforms, with different absorption
and distinctive gene expression profiles. To our knowledge,
this is the first study focused on the effect of FA from CLA-
enriched egg yolks on transcriptional activation of PPARs
(PPAR𝛼, PPAR𝛾, and PPAR𝛿). All experiments included as
controls synthetic CLA isomers as well as standard agonists
and antagonists of different PPARs. Our results showed that
EFA-CLA extract exhibits the properties of agonists for all
PPAR isoforms (Figures 3(a)–3(c)); however, those properties
seem to bemost selective towards PPAR𝛾 (Figure 4). Interest-
ingly, PPAR𝛾 has been associated with the greatest impact on
cancer cell proliferation, survival, and differentiation, and its
ligands are associated with anticancer properties [33, 34]. In
addition, as observed for EFA-CLA, transactivation of PPAR
receptors is more effective compared to fatty acids extracted
from a nonenriched egg yolk (EFA) (Figures 3(a)–3(c)).
Since cis9,trans11CLA isomer showed PPAR agonist activity
(Figures 3(a)–3(c)) and since this isomer was 3-fold more
efficiently incorporated into egg yolks than trans10,cis12CLA
[23], it could be hypothesized that cis9,trans11CLA plays a
significant role in EFA-CLA-mediated activation of PPARs.
The effect of synthetic CLA isomers provided us
with important information about their specificity. While
cis9,trans11 isomer acted as a PPAR agonist (Figures
3(a)–3(c)), the antagonist effect was observed for trans10,cis12
isomer, specifically on PPAR𝛾 (Figure 3(c)). Available
literature is consistent with our results. cis9,trans11 isomer
has been reported to inhibit cell growth [15, 16] showing
antitumor properties [17–20]. It has been found as well
that the presence of trans10,cis12 isomer may abrogate
the antiproliferative activity of cis9,trans11 [18] and even
inhibit the activity of synthetic PPAR agonists [15]. Thus,
it is even more interesting that our results showed more
efficient reduction in cancer cells proliferation for EFA-CLA
treatment than using a pure synthetic cis9,trans11CLA
isomer that may suggest other factors including modified
SFA/MUFA ratio in enriched egg yolks [23], supporting
antiproliferative action of cis9,trans11CLA isomer.
PPARs act as transcription factors and regulate the
expression of dependent genes by binding to their PPREs.
Available literature gives a number of genes regulated by
PPARs; the ligand-dependent transcription factors [35] and
the expression of those genes can be both inhibited or
activated depending on the ligand, suggesting selectivity [36].
CLA isomers have been found to act as PPAR ligands and
shown to be involved in the inhibition of transcription of
genes including TNF [37], NFKB1 [38], and NR1I3 [39] as
well as transactivation: TGFB1 [40], BRCA1 [41], PTEN [42],
p21/WAF1/CDKN1A [43],CEBPA [44],ABCB4 [45], andAOX
[46]. Although a significant number of genes regulated by
PPARs have been described, the list is not exhaustive and
is constantly updated as new results are being published
from both experimental data and bioinformatics analyses
of promoter regions containing PPRE consensus sequences
(AGGTCANAGGTCA) (Figure 5).
In the current study, we applied bioinformatic tools
to find genes with PPRE and analyze the effect of CLA
on the expression of these genes. To our knowledge, we
proposed several new genes that could be potentially PPAR-
regulated: BCAR3, LZTS, SLC5A, TCF20,WT1, ZNF621, and
THRB (transcript TR𝛽2) (Table 2). Since preliminary data
showed that some of themwere strongly regulated by PPARs,
we studied the expression of TCF20, WT1, THRB (TR𝛽2),
and ZNF621 genes in the context of various PPAR ligands,
including EFA-CLA.
First one TCF20 can act as a phosphoserine-specific
repressor of estrogen receptors (ER) in estrogen-dependent
tumors [47]. MCF-7 human breast carcinoma cell line is
estrogen receptor (ER) positive; thus, the expression of
TCF20 should inhibit ER and consequently impair the viabil-
ity of the tumor cells. Our results confirm these assumptions,
showing elevated TCF20 mRNA level in cells treated with
EFA-CLA. This effect was much stronger than for EFA
(Table 2). Interestingly, themost pronounced effectwas found
for trans10,cis12CLA isomer (Table 2), which may explain its
advantages over the cis9,trans11CLA in reducing the viability
ofMCF-7 (positively correlateswith its effect on the reduction
in cell viability) (Figure 1). In contrast to Pariza et al. [18],
this result also suggests that trans10,cis12CLA isomer could
support antiproliferative action of cis9,trans11CLA in EFA-
CLA via transcription-enhancing effects on TCF20.
Available literature addresses the relationship between
receptors encoded by PPAR and THRB genes [48–50]. THRB
encodes three isoforms of human thyroid hormone receptor:
TR𝛽1 and tissue-specific TR𝛽2 and TR𝛽4, which are thought
to be engaged in cell cycle control and metabolism [51].
Recently, THRB has been studied as a tumor suppressor [52].
Although TR𝛽1 isoform has been found to play a role in the
competitive inhibition of the PPAR transactivation [53], there
is limited information on the relationships between TR𝛽2
and PPAR receptors. TR𝛽 and PPAR receptors are linked by
the same obligatory coreceptor, retinoid X receptor (RXR),
that binds to their heterodimeric partners before binding to
DNA. Although RXR plays a central role in regulating the
activity of a number of nuclear hormone receptors including
TR𝛽 and PPARs by acting as a heterodimeric partner, this
receptor is known to be constitutively expressed in cells [53];
therefore, focusing on PPARs, we do not show the expression
of RXR in this paper. Nevertheless, it has been reported
that TR𝛽 and PPAR receptors can compete for binding
to RXRs in the nucleus [54]. Since we have found PPRE
within the sequence of TR𝛽2-specific promoter, located in
intron IV of THRB gene, the bidirectional regulation of
TR𝛽2 and PPARs is thought to be more complex. Results
presented in the current manuscript indicated enhanced
transactivation of TR𝛽2 by all PPARs isoforms in response
to the treatment with experimental FA (Table 2) that may be
evidence of the functional activity of the TR𝛽2-specific PPRE;
however, this needs further studies. The most significant
effect wasmeasured for the synthetic CLA isomers, especially
10 PPAR Research
trans10,cis12 (Table 2). Taken together, our findings showed
that transcription levels of TR𝛽2 are elevated by PPARs and
their agonists. Simultaneously, TR𝛽1 isoform has been shown
to compete with PPAR for access to the RXR coreceptor
or for PPRE binding sites in promoter regions of regulated
genes [50] that could suggest TR𝛽1-mediated inhibitory role
in expression of TR𝛽2 isoform and possibly other PPAR-
responsive genes.
WT1 gene, as a transcription factor, directly or indirectly
interacts with a number of genes involved in cell cycle
and neoplasia, including HIF1A, AREG, SRY, NROB1, SOX9,
IGF2,MDM4, BRCA1, TP53, and SP1 (NCBI Gene). Available
literature suggests an oncogenic nature ofWT1 andhas shown
its overexpression in various tumors and tumor cell lines,
especially in breast cancer cells and melanoma [55, 56]. In
addition, decreased levels ofWT1 gene expression correlated
with reduced cell proliferation in both melanoma and breast
cancer cells [57, 58].WT1 has also been linkedwithmalignant
transformation in breast cancer, and its overexpression asso-
ciated with reduced susceptibility to drug treatment. Indeed,
it has been shown for estrogen-dependent lines that WT1
positively regulates the expression of EGFR and HER2 [55],
contributing to the resistance to hormone therapy [59, 60]. In
melanoma, in vitro WT1 silencing resulted in decreased cell
proliferation, followed by apoptosis induction with caspase-
3 activation [61], while in vivo it reduced the melanoma
metastatic to lungs [56]. On the other hand, some studies
indicate that pharmacologic activation of PPAR𝛿 by its
agonists (GW0742 and GW501516) inhibited proliferation of
themurinemelanoma cells, accompanied by downregulation
of WT1 [62]. It was suggested that PPAR𝛿 can act via the
PPRE in theWT1 promoter and directly suppress its activity;
however, our results do not support this hypothesis. Although
the use of a known PPAR𝛿 agonist, GW0742, resulted in
PPAR𝛿 activation (Figure 3(b)), no decrease in the expression
of WT1 was measured (Table 1). This contradiction may
result from the use of different biologicalmaterials suggesting
cell/tissue-specific regulation and/or association/dissociation
of different corepressors or coactivators to transcription
machinery. Interestingly, we showed that treatmentwithEFA-
CLA and cis9,trans11 reduced expression of WT1 via the
activation of PPAR𝛿 (Table 2). A similar effect was observed
for other experimental FA (Table 2) suggesting that various
PPAR ligands may exert different effects in different cells;
however, this hypothesis should be studied.
5. Conclusion
In conclusion, potential tumor suppressor properties of PPAR
receptors make their ligands attractive candidates for the
development of new chemopreventive, anticancer agents.
Here, we show for the first time a functional food product,
CLA-enriched egg (EFA-CLA), that is more effective in
reducing of MCF-7 cancer cells proliferation than synthetic
CLA isomers. This EFA-CLA effect could result from the
high content of cis9,trans11 isomer, altered SFA/MUFA ratio
in enriched egg yolks, and/or supportive role of trans10,cis11
isomer in regulation of specific genes. Our results indicate
that EFA-CLA can act as a ligand of PPARs, showing an
agonist activity, specifically towards the PPAR𝛾 isoform.
Control, synthetic cis9,trans11 isomer of CLA exerted an
agonist effect on all PPAR receptors, while trans10,cis12
showed no effects or even acted as an antagonist of PPAR𝛾.
However, this isomer was able to regulate some specific
genes containing PPREs such as TCF20 involved in cell cycle
arrest. Simultaneously, cis9,trans11 isomer upregulated THRB
suppressor and downregulated WT1 oncogene showing a
small part of a PPAR action that in case of EFA-CLA leads to
the observed reduction in proliferation of the breast cancer
cells. It seems therefore that CLA-enriched eggs could be
considered as food products with anticancer potential.
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